Severe congenital neutropenia (SCN) is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development. With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), SCN patients are now surviving longer, but are at increased risk of developing myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after malignant transformation are not well established. We report results for six patients with SCN who underwent HSCT for MDS or AML between 1997 and 2001 at two transplant centers. Two patients transplanted for MDS survived. Both of these patients were transplanted without being given induction chemotherapy. Four patients, who all received induction chemotherapy for AML prior to HSCT, died. Administering induction chemotherapy prior to HSCT resulted in significant morbidity. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS/AML is established. SCN patients should be monitored carefully for progression to MDS in order to be treated with HSCT as soon as they have progressed and before developing AML. For SCN patients who progress to AML, HSCT should still be considered, even though the risks appear to be greater.
plantation; myelodysplastic syndrome; acute myelogenous leukemia; recombinant-methionyl human granulocytecolony-stimulating factor Severe congenital neutropenia (SCN) refers to a group of hematologic conditions associated with low blood neutrophil counts and recurrent infections. 1 Kostmann syndrome (KS) is a subtype of SCN that was originally described in a Swedish population with congenital neutropenia and an autosomal recessive inheritance pattern. 2, 3 KS patients have neutropenia recognized from birth or shortly thereafter, accompanied by life-threatening bacterial infections. SCN patients have the same hematologic phenotype and clinical presentation as KS, without a defined pattern of inheritance. Often the diagnostic terms KS and SCN are used interchangeably, regardless of inheritance. The preferred designation for this patient population is SCN. 4 The bone marrow of SCN patients is characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development, 5, 6 resulting in absolute neutrophil counts (ANC) in the range of 0-0.2 Â 10 9 /l. The estimated frequency of SCN is 1-2 cases per million, with both genders equally affected. 7 The introduction of recombinant human granulocytecolony-stimulating factor (r-HuG-CSF ) in 1987 8, 9 significantly reduced the incidence of death secondary to severe infections for most SCN patients. 10, 11 A majority (90%) of SCN patients respond to r-HuG-CSF with an increase in ANC toX1.0 Â 10 9 /l. As a result, r-HuG-CSF continues to be the therapy of choice for these patients, and a majority of SCN patients now survive past infancy. 4 For those refractory to r-HuG-CSF, transplantation of hematopoietic stem cells is an effective treatment, especially when the donor is an HLA-identical sibling. 12, 13 It is now well established that patients with SCN are at risk for development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). [14] [15] [16] [17] [18] In a recent report, 19 375 SCN patients were followed for the development of MDS or AML. The cumulative incidence of MDS/AML was 9% after 6 years of therapy, and increased to 23% after 10 years and 33% after 12 years, highlighting the potential danger of malignant transformation in this disorder.
The results of combination chemotherapy in treating MDS/AML in SCN patients have been disappointing, with no reports of long-term survival. Hematopoietic stem cell transplantation (HSCT) has been the only curative approach for patients with MDS/AML, 12 but there are few reports of outcomes of transplantation after the development of MDS/AML. 20 In this study, we summarize the outcome for six patients with SCN who underwent HSCT for either MDS or AML in two centers between 1997 and 2001.
Methods

Patients
SCN patients who were transplanted for MDS or AML were eligible to participate in this retrospective study. Data were collected through an Institutional Review Board (IRB) approved retrospective chart review. Patient characteristics are outlined in Table 1 .
Malignant transformation (cytogenetic studies and immunophenotyping)
The diagnosis of MDS or AML was established by bone marrow examination, flow cytometry, and cytogenetic studies ( Table 1) .
Pretransplant conditioning regimens and hematopoietic stem cell donors
The conditioning regimen for five patients was busulfan 1 mg/kg every 6 h orally for 16 doses, cytarabine 2 g/m 2 intravenously every 12 h for four doses, and cyclophosphamide 60 mg/kg intravenously daily for two doses. One patient received total body irradiation of 1350 cGy divided in 225 cGy fractions daily for 6 consecutive days and cyclophosphamide 60 mg/kg intravenously daily for two doses. GVHD prophylaxis consisted of tacrolimus 0.03 mg/kg continuous intravenous infusion or cyclosporine 0.3 mg/kg continuous intravenous infusion and shortcourse methotrexate 5 mg/m 2 intravenously on days þ 1, þ 3, þ 6, and þ 11 following HSCT. An HLA-identical sibling was available for one patient. For the other five patients, hematopoietic stem cells were procured from the best-matched unrelated donor through the National Marrow Donor Program (NMDP) ( Table 2 ). Only patient 1 was matched for HLA-A, -B, and -C and for DRB1 and DQB1 by high-resolution techniques. The remaining patients were matched for class I by intermediate DNA typing and for class II by high-resolution techniques. HLA-C was not matched for these patients.
Results
Three boys and three girls between the ages of 4 and 20 years were transplanted. The post transplantation median follow-up is 4.2 years. The duration of r-HuG-CSF use prior to leukemic transformation in this series of patients ranged from 4 to 13 years with a median of 9.3 years. Five of the six patients developed either MDS or AML during the second decade of life, whereas only one developed MDS at the age of 4 years. The transplant characteristics and outcomes are summarized in Table 2 .
Two of the six patients (patients 1 and 2) were transplanted for MDS, and they remain alive at 2.7 years and 4 years, respectively. Neither received pre-HSCT chemotherapy. Their transplants took place at 5 and 1 months from diagnosis, respectively.
Patient 1 received a matched unrelated donor bone marrow transplant (BMT) for MDS diagnosed at 4 years of age. Her post-HSCT course was complicated by acute GVHD involving the skin and gastrointestinal tract, followed by chronic GVHD of the gastrointestinal tract. Late complications have included occasional bacterial infections and autoimmune hemolytic anemia. She remains on immunosuppression 2.5 years following her HSCT.
Patient 2 received a matched related peripheral blood stem cell transplant at the age of 18 years for MDS. His post-HSCT course has been complicated by mild chronic GVHD of his eyes, mouth, and skin. Although he remains on low-dose immunosuppression 4 years following his transplant, he has been able to work and attend school full-time.
Four patients were transplanted for AML. All four received induction chemotherapy and were in remission prior to an unrelated donor HSCT. There were no survivors.
Induction chemotherapy caused significant morbidity in these patients. In addition to prolonged pancytopenia and severe mucositis in all patients, life-threatening infections developed in two patients. In one case (patient 4), Streptococcus mitis sepsis was complicated by septic shock. [20] a Previously published in White et al.
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In the other case (patient 5), pulmonary aspergilloma with fungemia was exacerbated by acute respiratory distress syndrome, disseminated intravascular coagulation, and acute renal failure. Following recovery from induction chemotherapy, matched unrelated HSCT was undertaken in two patients (patients 3 and 4). Both patients developed steroidresponsive acute GVHD. Chronic GVHD was the cause of death for both patients.
The other two patients (patients 5 and 6) developed primary graft failure after receiving single-antigen-mismatched unrelated donor transplants. Attempts to reverse the graft failure were unsuccessful in both cases. Patient 5 died 4 days after a second transplant from the same donor performed 42 days after the initial BMT. In patient 6, the primary graft failure could not be reversed despite a second transplant from the same donor 31 days from the initial BMT. Transient engraftment followed transplantation of high-dose CD34-selected stem cells from his haploidentical father 77 and 134 days from initial BMT. However, engraftment could not be sustained and he died from relapsed AML 223 days post transplant.
Annual bone marrow examinations and cytogenetic findings
All six patients received annual bone marrow examinations with cytogenetic analyses as recommended by the Severe Congenital Neutropenia International Registry (SCNIR) Advisory Board. In four patients with no prior evidence of MDS/AML, the diagnosis was made 3, 10, 10, and 18 months after their most recent normal bone marrow aspirate. In two patients, clonal abnormalities were detected 5 months and 2 years prior to the diagnosis of AML. Patient 3 had morphologic findings suggestive of MDS, but normal cytogenetics, 5 months prior to the diagnosis of AML. Falling blood counts prompted a repeat bone marrow examination, which revealed progression to AML. In patient 5, an isochromosome of 17q was initially detected during a routine bone marrow examination 2 years prior to the diagnosis of AML. The prognostic significance of this finding was unknown and the patient was followed expectantly. Subsequent annual examinations revealed clonal evolution with the addition of trisomy 8, and finally, when AML was diagnosed, also trisomy 21. Chromosome 21 abnormalities were present in five out of six cases (Table 1) .
Discussion
HSCT from an HLA-identical sibling is beneficial for SCN patients refractory to r-HuG-CSF and without evidence of leukemic transformation. 13 However, little has been reported on the outcome of HSCT performed after the development of overt MDS/AML. In this series, four of the five SCN patients who underwent transplantation for leukemic transformation from unrelated donors died. The 5-year overall survival for recipients of unrelated donor transplants for MDS or AML ranges from 27 to 50%. 21, 22 The outcomes in this series are not clearly inferior to the registry data, but it is possible that SCN patients who have transformed to MDS/AML are at particularly high risk for 23 Busulfan levels were not ascertained routinely at our center at the time of these transplants. Thus, while rejection may be explained by well-understood mechanisms, we remain open to the possibility that a more unique mechanism may be operative. In addition to the two primary graft failures observed in our patients, unpublished data from the SCNIR (written communication, A Bolyard, December 2001) reports graft failure in six out of the first 12 partially matched transplants, which includes haploidentical parental transplants and mismatched unrelated donor HSCT. While highly speculative, it is also possible that patients with SCN have altered microenvironments, with or without long-term r-HuG-CSF therapy, which is less hospitable for transplanted stem cells.
Intensive induction chemotherapy prior to conditioning regimens caused significant morbidity and may have played a role in the poor outcomes, as seen in patients 3, 4, 5, and 6. Of particular interest, neither of the two survivors (patients 1 and 2) received pre-HSCT chemotherapy. Once the diagnosis of MDS was established, HSCT was performed as soon as possible. In future patients, we plan to avoid intensive induction chemotherapy, whenever possible.
The presence of MDS in four patients (patients 1, 2, 3, and 5) and cytogenetic abnormalities in five patients (1) (2) (3) (4) (5) suggests that there is a window between the development of MDS and the progression to AML. In patients 3 and 5, AML evolved from previously detected MDS, which was diagnosed 11 and 25 months earlier, respectively. Both received intensive induction chemotherapy, followed by unrelated donor transplants, and subsequently died. If there is a window between the development of MDS and progression to AML, HSCT with the best available donor could be undertaken without giving induction chemotherapy. In non-SCN patients, the time from diagnosis of MDS/AML to HSCT is a vital prognostic factor. [24] [25] [26] The standard of care for SCN patients currently includes quarterly complete blood counts with white blood cell differential counts, as well as annual bone marrow examinations, including cytogenetic studies. In this series, MDS/AML was detected between 3 and 18 months from their most recent normal bone marrow examinations. In four cases, falling counts prompted the marrow examination, whereas in the other two patients, low blood counts were noted at the time of scheduled marrow examination. Therefore, monthly complete blood counts and biannual bone marrow examinations, including cytogenetic studies, might be prudent to detect early malignant changes. Ultimately, closer monitoring may facilitate more expeditious transplants. Examinations may need to be conducted for many years before significant findings occur. In our series, MDS or AML was diagnosed during the second decade of life in five out of six patients, which is the time of peak incidence. 27 Dysplasia can be difficult to detect from a routine bone marrow aspirate examination. Cytogenetic analyses offer the benefit of detecting clonal abnormalities suggestive of malignant transformation. In our series, chromosome 21 abnormalities were observed in five of the six patients. The most common reported cytogenetic abnormalities detected in the bone marrows of SCN patients who develop MDS/ AML are abnormalities of chromosome 7 (monosomy 7 or del(7q)), 27, 28 followed by abnormalities involving chromosome 21. [29] [30] [31] [32] Of 31 SCN patients who developed MDS/ AML, 18 patients acquired a partial or complete loss of chromosome 7 in bone marrow cells, and nine patients showed abnormalities of chromosome 21 (six of which were trisomy 21). These findings were often seen together in the same patient. 30 In conclusion, poor survival is the hallmark of patients who develop MDS/AML arising in the context of SCN. In this small series, the only survivors were two patients transplanted for MDS without receiving pre-HSCT chemotherapy. Rapid transplantation should be the goal for the SCN patient once the diagnosis of MDS or AML is established. SCN patients need to be followed carefully for progression to MDS and should be treated with HSCT once MDS is recognized and before developing AML. It is possible that earlier identification of MDS, by closer monitoring, may improve survival in SCN patients undergoing transplantation. For SCN patients who unfortunately progress to AML, HSCT should be performed as soon as possible, preferably before intensive chemotherapy.
